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Caffeic Acid Phenethyl Ester Possessing Various
Immunomodulatory Effects Is a Potentially Effective
Therapy for AsthmaAsthma is one of the most common chronic disorders in
childhood, which imposes a growing burden on society
in terms of morbidity, quality of life, and health care costs.
In addition to current medications, such as bronchodilator,
inhalation of corticosteroid, leukotriene modifier, and anti-
immunoglobulin E (IgE) antibody, some traditional medi-
cines have also shown the therapeutic effect on asthma.
Propolis, a natural resinous product collected by honey-
bees, has exhibited various biological activities. In an
ovalbumin-sensitized airway inflammatory animal model,
propolis extracts could suppress the serum levels of oval-
bumin-specific IgE and immunoglobulin G1 (IgG1) and
airway hyperresponsiveness.1 Moreover, propolis was used
as an adjuvant to treat patients with mild to moderate
asthma in a clinical trial. The results showed that the
number of nocturnal asthma attacks significantly decreased
and the lung function improved in patients receiving
propolis.2
Although propolis appears to be effective in asthma
treatment, the clinical application of it is not currently
suggested. The major concern is the highly variable
composition of propolis that limits the standardization and
raises the safety issues. Propolis contains resin and vege-
table balsam, wax, essential and aromatic oils, pollen,
minerals, and a mixture of biologically active chemicals,
including terpenes, cinnamic acid, caffeic acid and their
esters, amino acids, and flavonoids. Of them, caffeic acid
phenethyl ester (CAPE) is extensively studied and found to
have antitumor, antioxidant, anti-inflammatory, and other
immunomodulatory properties.3,4 CAPE has been shown to
inhibit mitogen-induced human T-cell proliferation and the
production of cytokines, such as interferon-g and inter-
leukin (IL)-5. It can also induce active caspase-3 expression
in CD4þ T cells, especially Type 2 T helper cells.3 In this
issue of the journal, Sy et al5 found that CAPE could further
enhance transforming growth factor-b production by1875-9572/$36 Copyright ª 2011, Taiwan Pediatric Association. Publish
doi:10.1016/j.pedneo.2011.10.001peripheral blood mononuclear cells from asthmatic chil-
dren. Of note, transforming growth factor-b is a powerful
anti-inflammatory cytokine that can efficiently block the
Type 2 T helper cellerelated inflammation.
During the process of allergic inflammation, allergens
are captured, processed, and presented to T cells by
antigen presenting cells. Dendritic cells are professional
antigen presenting cells, and the effect of CAPE on func-
tions of human monocyte-derived dendritic cells (MoDCs)
has been well studied. The results showed that CAPE
significantly inhibited IL-12, IL-10, and immune protein-10
production by MoDCs derived from healthy controls,
whereas it inhibited IL-10 and immune protein-10 but not
IL-12 expression in allergic patients’ MoDCs stimulated by
crude mite extract. CAPE was also found to interfere with
inhibitor of kappa B-alpha (IkBa) phosphorylation and
nuclear factor-kB activation in human MoDCs, indicated by
blocking the NF-kB signaling pathway; CAPE has the ability
to inhibit cytokine and chemokine production by MoDCs.4 In
addition to immune cells, CAPE could affect other cells.
Through signal transducer and activator of transcription 6
inhibition, Lin et al6 recently revealed that CAPE sup-
pressed the production of eotaxin in cytokine-stimulated
human lung fibroblasts in a dose-dependent manner that
may subsequently decrease the influx of eosinophils.
Taken together, CAPE with certain immunomodulatory
functions may provide another therapeutic option for
asthma. In the future, it is needed to conduct more animal
studies and human clinical trials to investigate the safety and
clinical effectiveness of CAPE in the treatment of asthma.
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